Cara Therapeutics | CARA - Ebitda


Cara Therapeutics reported $-2.39M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Cipla INR 14.03B 4.48B Jun/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
J&J USD 8.27B 1.08B Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.01B 18M Jun/2026
RedHill Biopharma USD 2.69M 108.46M Jun/2023
Supernus Pharmaceuticals USD 31.6M 2.37M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024